 BRYAN, Texas, Dec. 08, 2020 GLOBE NEWSWIRE -- iBio, Inc. NYSEA:IBIO iBio or the Company, a biotech innovator and biologics contract manufacturing organization, today announced the pricing of its underwritten public offering of approximately 29.7 million shares of its common stock for gross proceeds of 35.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by iBio. The offering is expected to close on or about December 10, 2020, subject to customary closing conditions. In addition, iBio has granted the underwriter a 30-day option to purchase up to approximately 4.4 million additional shares of its common stock. 